Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance
Reference number: TA269
Published: 12 December 2012
Last updated: 01 January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
02 November 2012
(190.34 Kb 55 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 29 October 2012